Clinical Trial

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for early resectable NSCLC patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-01-05; most recent amendment 2024-11-21.
Status change: Recruiting → Active, Not Recruiting 2023-02-08
Trial Details
NCT Number NCT04699721
Lead Sponsor Xiangya Hospital of Central South University
Conditions Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB
Enrollment 60 participants
Start Date 2020-07-01
Primary Completion 2027-09 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-22